PR Newswire Clinical TrialsOriginal article
New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
ConferencepositiveLeqembiPositive
AI Analysis
Summary
Eisai presented clinical data at AAIC 2026 showing that Leqembi's subcutaneous autoinjector formulation demonstrates similar efficacy and safety to the IV formulation in early Alzheimer's disease patients. The data supports the development of this alternative administration route for the approved Alzheimer's treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Subcutaneous autoinjector formulation demonstrated similar efficacy and safety to IV formulation in early Alzheimer's disease
Importance:6/10
Sentiment:
0.70
Alzheimer's diseasesubcutaneous formulationclinical dataAAIC 2026lecanemab
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 13, 2026 4:08 AM